Contributors |
|
xi | |
|
A Islet auto-transplantation |
|
|
|
Section I Chronic pancreatitis |
|
|
|
1 Etiopathogenesis and pathophysiology of chronic pancreatitis |
|
|
|
|
|
|
|
|
|
7 | (1) |
|
Alcohol-induced chronic pancreatitis |
|
|
7 | (2) |
|
|
9 | (1) |
|
|
10 | (2) |
|
|
12 | (1) |
|
Recurrent acute pancreatitis |
|
|
13 | (1) |
|
|
13 | (1) |
|
|
14 | (1) |
|
Sphincter of Oddi dysfunction |
|
|
14 | (1) |
|
|
15 | (1) |
|
Tropical chronic pancreatitis |
|
|
16 | (1) |
|
Drug toxicity-induced pancreatitis |
|
|
16 | (1) |
|
|
17 | (1) |
|
|
17 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
19 | (1) |
|
Endocrine insufficiency and diabetes mellitus |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
21 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
23 | (1) |
|
|
23 | (1) |
|
Molecular mechanisms in the development of pancreatitis |
|
|
24 | (1) |
|
|
24 | (1) |
|
|
25 | (8) |
|
2 Nonreplacement treatment of chronic pancreatitis: Conservative, endoscopic, and surgical (resection and drainage procedures) |
|
|
|
|
|
|
|
33 | (1) |
|
|
33 | (3) |
|
Medical and conservative management |
|
|
36 | (1) |
|
Endoscopic and surgical management of chronic pancreatitis |
|
|
37 | (9) |
|
|
46 | (1) |
|
|
46 | (5) |
|
Section II Islet auto-transplantation for chronic pancreatitis |
|
|
|
3 Requirements for clinical islet laboratories |
|
|
|
|
|
|
|
51 | (1) |
|
Allogeneic vs autologous islet |
|
|
52 | (1) |
|
Registration with the FDA |
|
|
53 | (3) |
|
Registration with other regulatory agencies |
|
|
56 | (1) |
|
General requirements for a clinical auto islet lab |
|
|
56 | (1) |
|
Facilities and environmental control |
|
|
56 | (3) |
|
|
59 | (2) |
|
|
61 | (1) |
|
|
62 | (2) |
|
|
64 | (1) |
|
|
64 | (3) |
|
4 Islet isolation for autotransplantation, following total or near total pancreatectomy |
|
|
|
|
|
|
67 | (1) |
|
|
68 | (16) |
|
|
84 | (1) |
|
|
85 | (2) |
|
|
87 | (2) |
|
5 Strategies to improve islet yield from chronic pancreatitis pancreases intended for islet allotransplantation |
|
|
|
|
Gopalakrishnan Loganathan |
|
|
|
|
|
|
|
|
89 | (1) |
|
|
90 | (1) |
|
Pancreatectomy and pancreas transport |
|
|
91 | (1) |
|
Trimming and cannulation of the pancreas |
|
|
91 | (1) |
|
Enzyme selection and perfusion |
|
|
92 | (1) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
96 | (1) |
|
|
97 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
|
98 | (3) |
|
6 Surgical techniques for total pancreatectomy and islet autotransplantation |
|
|
|
|
|
|
|
|
101 | (1) |
|
Indications and contraindications |
|
|
102 | (2) |
|
|
104 | (7) |
|
Percutaneous infusion/transplantation of islets |
|
|
111 | (1) |
|
|
111 | (1) |
|
|
112 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
114 | (1) |
|
|
114 | (1) |
|
|
114 | (1) |
|
|
114 | (3) |
|
7 Total pancreatectomy with islet autotransplantation in children |
|
|
|
|
|
|
|
|
117 | (1) |
|
|
117 | (2) |
|
Determining when TPIAT is indicated for the management of children with pancreatitis |
|
|
119 | (1) |
|
Surgical procedure and islet isolation and transplant in children |
|
|
119 | (1) |
|
Postoperative management of the child after TPIAT |
|
|
120 | (2) |
|
Short-term and long-term outcomes after TPIAT in children |
|
|
122 | (2) |
|
|
124 | (1) |
|
|
124 | (3) |
|
8 Islet autotransplantation: Indication beyond chronic pancreatitis |
|
|
|
|
|
|
|
|
|
|
|
127 | (1) |
|
Incidence of pancreatogenic diabetes after pancreatic resection |
|
|
128 | (1) |
|
Autologous islet transplantation to prevent or minimize pancreatogenic diabetes in patients requiring total pancreatectomy for chronic pancreatitis |
|
|
129 | (1) |
|
Expanding indications for IAT: Nonneoplastic diseases beyond chronic pancreatitis |
|
|
129 | (2) |
|
Expanding indications for IAT: Neoplastic benign diseases |
|
|
131 | (1) |
|
Expanding indications for IAT: Neoplastic malignant diseases |
|
|
132 | (1) |
|
Expanding indications for IAT: Milan protocol |
|
|
132 | (1) |
|
|
133 | (1) |
|
|
134 | (7) |
|
|
|
9 Postoperative care and prevention and treatment of complications following total pancreatectomy with islet cell autotransplantation |
|
|
|
|
|
|
|
141 | (1) |
|
Patient selection and preoperative preparation |
|
|
142 | (1) |
|
Postoperative management and complications |
|
|
142 | (4) |
|
|
146 | (1) |
|
|
147 | (2) |
|
10 Metabolic outcomes after total pancreatectomy followed by islet autotransplantation (TPIAT): Mixed blessings |
|
|
|
|
History and rationale for TPIAT: Points of view |
|
|
149 | (1) |
|
Favorable metabolic outcomes: Normal levels of glycemia, HbA1c, and β-cell function |
|
|
150 | (1) |
|
Unfavorable metabolic outcomes: Hypoglycemia following meals and exercise and deficient a-cell counter-regulatory response |
|
|
151 | (4) |
|
The need to consider nonhepatic transplantation sites |
|
|
155 | (1) |
|
|
155 | (2) |
|
11 Long-term results of TPIAT |
|
|
|
|
|
|
|
|
|
|
157 | (1) |
|
|
158 | (1) |
|
Gastrointestinal function outcomes |
|
|
159 | (2) |
|
Pain and quality of life outcomes |
|
|
161 | (1) |
|
|
162 | (1) |
|
Survival and cost of care |
|
|
163 | (2) |
|
|
165 | (1) |
|
|
165 | (6) |
|
B Bioengineering and regeneration of the endocrine pancreas |
|
|
|
Section I Pancreas development and regeneration |
|
|
|
12 Embryonic development of the endocrine pancreas |
|
|
|
|
|
Introduction to pancreas development |
|
|
171 | (1) |
|
|
172 | (5) |
|
Postnatal islet development and function |
|
|
177 | (2) |
|
|
179 | (1) |
|
|
180 | (1) |
|
|
180 | (3) |
|
13 Human pancreatic progenitors |
|
|
|
Mirza Muhammad Fahd Qadir |
|
|
|
|
|
|
183 | (1) |
|
Induction and patterning of pancreatic endoderm |
|
|
184 | (4) |
|
Lineage specification, proliferation, and compartmentalization of pancreatic progenitors |
|
|
188 | (3) |
|
Adult pancreatic progenitors |
|
|
191 | (1) |
|
Transdifferentiation in the pancreas |
|
|
192 | (1) |
|
Extrapancreatic sources of pancreatic precursors |
|
|
192 | (1) |
|
Mesenchymal stem cells as potential sources for pancreatic endocrine cells |
|
|
193 | (2) |
|
Therapeutic modulation of pancreatic regeneration and P-cell mass |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
195 | (1) |
|
|
196 | (5) |
|
14 Strategies to promote beta-cell replication and regeneration |
|
|
|
|
|
201 | (1) |
|
Beta-cell replication is the major contributor to the postnatal beta-cell growth |
|
|
202 | (2) |
|
Cell-cell communications regulate beta-cell proliferation |
|
|
204 | (2) |
|
Molecular signaling pathways that control beta-cell proliferation |
|
|
206 | (2) |
|
|
208 | (1) |
|
|
208 | (7) |
|
15 Diet as a therapeutic approach to diabetes management and pancreas regeneration |
|
|
|
|
|
|
215 | (1) |
|
Proper nutrition is key to the maintenance of P-cell homeostasis and function |
|
|
216 | (2) |
|
Dietary intervention for T1D: Feasibility, outcome, and recent progress |
|
|
218 | (2) |
|
Diet in T2D; The two sides of diet and eating habits as causing factor and potential treatment for T2D |
|
|
220 | (1) |
|
Dietary recommendations for women with gestational diabetes |
|
|
221 | (1) |
|
Clinical relevance of fasting or fasting-like regimens as a nutritional therapeutic approach in diabetes |
|
|
222 | (1) |
|
Molecular mechanisms supporting the potential of fasting and FMD to promote pancreas functional restoration |
|
|
223 | (2) |
|
|
225 | (1) |
|
|
225 | (4) |
|
16 The benefits of metabolic/bariatric surgery on diabetes mellitus |
|
|
|
|
|
|
229 | (1) |
|
History of metabolic/bariatric surgery |
|
|
230 | (3) |
|
Metabolic/bariatric surgery for diabetes |
|
|
233 | (2) |
|
Nonbariatric metabolic surgery for diabetes |
|
|
235 | (1) |
|
Metabolic/bariatric surgery mechanisms |
|
|
235 | (2) |
|
|
237 | (1) |
|
|
238 | (1) |
|
|
238 | (1) |
|
|
238 | (5) |
|
Section II Scaffolds for endocrine pancreas bioengineering |
|
|
|
17 ECM-based scaffolds for pancreas bioengineering |
|
|
|
|
|
243 | (1) |
|
|
244 | (1) |
|
Extracellular matrix in pancreatic islets |
|
|
244 | (2) |
|
Tissue engineered islet scaffold incorporating ECM |
|
|
246 | (1) |
|
Whole organ engineering of pancreas |
|
|
246 | (5) |
|
Hybrid organs using repurposed biological scaffolds: Liver and kidney to pancreas |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
252 | (5) |
|
18 Plasma scaffolds for islet transplantation |
|
|
|
|
|
257 | (1) |
|
|
257 | (1) |
|
Integrins and mechanotransduction |
|
|
258 | (1) |
|
|
259 | (1) |
|
Organoid organization protects islet from anoikis |
|
|
259 | (1) |
|
Strategies to counteract anoikis |
|
|
259 | (2) |
|
Using plasma as a scaffold |
|
|
261 | (2) |
|
Plasma scaffolds for islets: Drawbacks |
|
|
263 | (2) |
|
Uses of plasma for other applications |
|
|
265 | (1) |
|
|
265 | (1) |
|
|
265 | (1) |
|
Conflict of interest statement |
|
|
265 | (1) |
|
|
265 | (4) |
|
19 A biologic resorbable scaffold for tissue engineering of the endocrine pancreas: Clinical experience of islet transplantation on the omentum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Introduction: The intrahepatic site for islet transplantation |
|
|
269 | (1) |
|
Extrahepatic sites for islet transplantation |
|
|
270 | (1) |
|
The greater omentum: A novel site for islet transplantation |
|
|
270 | (5) |
|
|
275 | (1) |
|
|
275 | (2) |
|
20 Endothelialized collagen modules for islet tissue engineering |
|
|
|
|
|
|
277 | (1) |
|
Transplantation into the omental pouch of immune competent rats |
|
|
278 | (2) |
|
Subcutaneous transplantation into immune-compromised SCID/bg mice |
|
|
280 | (4) |
|
|
284 | (1) |
|
|
285 | (6) |
|
Section III Islet encapsulation |
|
|
|
|
|
|
|
|
291 | (3) |
|
Conformal coating technology |
|
|
294 | (12) |
|
Conclusion and future directions |
|
|
306 | (1) |
|
|
306 | (1) |
|
|
306 | (1) |
|
22 Co-encapsulation of ECM proteins to enhance pancreatic islet cell function |
|
|
|
|
|
|
|
307 | (1) |
|
Overview of the islet extracellular matrix |
|
|
308 | (1) |
|
Effects of ECM co-encapsulation on P-cell survival |
|
|
309 | (1) |
|
Effects of ECM co-encapsulation on P-cell function |
|
|
310 | (1) |
|
Effects of ECM co-encapsulation on p-cell proliferation |
|
|
311 | (1) |
|
|
311 | (1) |
|
|
312 | (3) |
|
23 Co-encapsulation of mesenchymal stromal cells to enhance islet function |
|
|
|
Vijayaganapathy Vaithilingam |
|
|
|
Type 1 diabetes and islet transplantation |
|
|
315 | (1) |
|
Current issues with encapsulated islet transplantation |
|
|
316 | (1) |
|
Mesenchymal stromal cells |
|
|
317 | (1) |
|
MSC and islet transplantation |
|
|
318 | (1) |
|
Islets and MSC co-encapsulation |
|
|
319 | (5) |
|
|
324 | (1) |
|
|
324 | (5) |
|
24 Silk-based encapsulation materials to enhance pancreatic cell functions |
|
|
|
|
|
|
|
|
|
329 | (1) |
|
|
330 | (2) |
|
Silk matrices used for islet culture and encapsulation |
|
|
332 | (4) |
|
Conclusions and future perspectives |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
336 | (3) |
|
|
|
|
|
|
|
|
339 | (1) |
|
Cell encapsulation technology |
|
|
340 | (1) |
|
Macroencapsulation devices |
|
|
340 | (2) |
|
|
342 | (1) |
|
|
342 | (5) |
|
Section IV Stem cells to generate insulin producing cells |
|
|
|
|
|
|
|
|
|
|
347 | (1) |
|
Regeneration of pancreatic islets |
|
|
348 | (2) |
|
Biliary tree stem/progenitor cells and the network of hepatic, biliary, and pancreatic stem/progenitor cell niches |
|
|
350 | (2) |
|
Pancreatic progenitor cells |
|
|
352 | (1) |
|
Pancreatic duct gland as the niche of pancreatic progenitors |
|
|
353 | (2) |
|
|
355 | (1) |
|
|
355 | (4) |
|
27 Human embryonic stem cells (hESC) as a source of insulin-producing cells |
|
|
|
|
|
|
|
|
|
359 | (2) |
|
Current therapeutic approaches and challenges |
|
|
361 | (1) |
|
|
362 | (1) |
|
Stem cell-derived p cells |
|
|
363 | (4) |
|
Hurdles still preventing a final functional product |
|
|
367 | (3) |
|
|
370 | (2) |
|
Current clinical trials of stem cells for diabetes |
|
|
372 | (1) |
|
Interspecies organogenesis and stem cells |
|
|
373 | (1) |
|
|
374 | (1) |
|
|
374 | (7) |
|
28 Human-induced pluripotent stem cells (iPSC) as a source of insulin-producing cells |
|
|
|
|
|
Pluripotent stem cells: Embryonic stem cells and somatic cell nuclear transfer |
|
|
381 | (1) |
|
Every cell can be pluripotent: The discovery of induced pluripotent stem cells |
|
|
382 | (1) |
|
iPSC are in the clinic: active protocols in humans |
|
|
383 | (1) |
|
iPSC for β-cell replacement: In vitro differentiation into β-cells |
|
|
384 | (4) |
|
Immunogenicity of iPSC-derived cells |
|
|
388 | (1) |
|
|
389 | (2) |
|
Safety of iPSC-derived cells |
|
|
391 | (1) |
|
|
392 | (1) |
|
|
392 | (5) |
|
29 Ductal cell reprograming to insulin-producing cells as a potential beta cell replacement source for islet auto-transplant recipients |
|
|
|
|
Gopalakrishnan Loganathan |
|
|
|
|
|
|
397 | (2) |
|
Ductal cells as a potential source for beta cell regeneration |
|
|
399 | (1) |
|
In vitro reprogramming of pancreatic ductal cells |
|
|
399 | (2) |
|
In vivo studies on the pancreatic ductal progenitor cells |
|
|
401 | (1) |
|
Controversies regarding endocrine differentiation from ductal lineages |
|
|
401 | (1) |
|
Conclusions and future perspectives |
|
|
402 | (1) |
|
|
403 | (1) |
|
|
403 | (1) |
|
|
403 | (4) |
|
30 Synthetic biology technologies for beta cell generation |
|
|
|
|
|
|
|
|
407 | (3) |
|
Synthetic biology approaches for generating beta cells |
|
|
410 | (4) |
|
Artificial designer cells |
|
|
414 | (2) |
|
Synthetic biology---Moving toward clinical applications |
|
|
416 | (1) |
|
|
417 | (6) |
|
Section V Animal-based platforms for pancreas bioengineering |
|
|
|
31 Xenotransplantation of the endocrine pancreas |
|
|
|
|
|
|
|
423 | (1) |
|
A brief history of xenotransplantation |
|
|
424 | (2) |
|
Optimizing the pig-to-NHP model |
|
|
426 | (1) |
|
Laying the foundation: preclinical studies in islet xenotransplantation |
|
|
427 | (9) |
|
Justification for translation to clinical trials |
|
|
436 | (2) |
|
|
438 | (1) |
|
|
439 | (1) |
|
|
439 | (1) |
|
|
439 | (1) |
|
|
439 | (8) |
|
32 Interspecies blastocyst complementation |
|
|
|
|
|
447 | (1) |
|
|
448 | (1) |
|
Generation of pancreas with IBC |
|
|
448 | (1) |
|
Transplantability of IBC pancreas |
|
|
449 | (1) |
|
|
449 | (1) |
|
Pretransplant immunogenicity |
|
|
450 | (1) |
|
Posttransplant immunogenicity |
|
|
451 | (1) |
|
Potential for IBC vasculature |
|
|
451 | (1) |
|
|
452 | (1) |
|
|
452 | (1) |
|
|
453 | (1) |
|
|
453 | (1) |
|
|
454 | (1) |
|
Suitability of large animal hosts |
|
|
455 | (1) |
|
|
455 | (1) |
|
|
456 | (1) |
|
|
456 | (5) |
|
Section VI Tissue engineering technologies applied to (J-cell replacement |
|
|
|
33 Bioengineering, biomaterials, and |3-cell replacement therapy |
|
|
|
|
|
|
|
|
|
|
|
461 | (1) |
|
Immunoprotective barrier strategy |
|
|
462 | (1) |
|
Revascularization strategy |
|
|
463 | (1) |
|
|
464 | (7) |
|
Islet delivery device fabrication techniques |
|
|
471 | (4) |
|
3D Printing in regenerative medicine |
|
|
475 | (2) |
|
|
477 | (3) |
|
|
480 | (6) |
|
|
486 | (1) |
|
34 Subcutaneous islet transplantation using tissue-engineered sheets |
|
|
|
|
|
|
|
|
Masaaki Hidaka Kojinatsuda |
|
|
|
|
|
|
|
|
487 | (1) |
|
Subcutaneous islet transplantation |
|
|
488 | (1) |
|
Cell sheet engineering in cell transplantation |
|
|
488 | (2) |
|
Subcutaneous islet transplantation using cell sheet engineering |
|
|
490 | (1) |
|
Our concept of subcutaneous islet transplantation using cell sheet engineering |
|
|
490 | (1) |
|
|
491 | (1) |
|
|
491 | (1) |
|
|
492 | (1) |
|
|
492 | (1) |
|
|
493 | (1) |
|
|
493 | (6) |
|
Section VII Regulation and funding |
|
|
|
35 Regulation for regenerative medicine-based therapies |
|
|
|
|
Regulatory approach to regenerative medicine in the EU |
|
|
499 | (1) |
|
Differences between United States and European Union regulatory framework |
|
|
500 | (1) |
|
Therapeutic use of pancreatic cells |
|
|
501 | (1) |
|
|
502 | (1) |
|
|
502 | (3) |
|
36 Catalyzing beta-cell replacement research to achieve insulin independence in type 1 diabetes: Goals and priorities |
|
|
|
|
|
505 | (1) |
|
|
506 | (8) |
|
Additional considerations |
|
|
514 | (1) |
|
|
515 | (1) |
|
|
515 | (1) |
|
|
515 | (2) |
|
|
517 | (3) |
|
37 Regenerative medicine technologies applied to beta cell replacement: The industry perspective |
|
|
|
|
Can a "replenishable" (stem cell-derived) beta cell therapy mimic islet transplant therapy? |
|
|
520 | (1) |
|
|
521 | (1) |
|
Beta cells within devices |
|
|
521 | (2) |
|
Can the therapy be removed and replaced? |
|
|
523 | (1) |
|
Can the therapy be mass-produced? |
|
|
523 | (1) |
|
|
523 | (1) |
|
|
524 | (1) |
|
|
524 | (1) |
|
|
524 | (1) |
|
|
524 | (2) |
|
|
526 | (1) |
|
38 Pancreas whole organ engineering |
|
|
|
|
|
|
|
527 | (1) |
|
Fundamental concepts of tissue development |
|
|
527 | (1) |
|
Three-dimensional bioscaffolds for whole organ pancreas engineering |
|
|
528 | (7) |
|
Challenges to current approaches |
|
|
535 | (1) |
|
|
535 | (2) |
Index |
|
537 | |